Xingyao Bu | Glioma | Best Researcher Award

Professor Xingyao Bu is the Chief Physician and Director of the Department of Neurosurgery at Juha International Center for Neurosurgery, Zhengzhou University People’s Hospital. A leading expert in precision minimally invasive therapy for gliomas, he specializes in in-vivo gene evolution and personalized treatment strategies. He has led 15 completed and two ongoing research projects, published 22 SCI papers, and holds 15 patents. As an editorial board member of multiple journals and a key figure in neurosurgical associations, his work in ctDNA research and precision medicine has significantly advanced glioma diagnosis, prognosis, and treatment.

Prof. Dr. Xingyao Bu | Zhengzhou University People’s Hospital | China

Experience

Currently serving as the Chief Physician and Director of the Department of Neurosurgery at Juha International Center for Neurosurgery, Zhengzhou University People’s Hospital, Professor Bu is also the Director of the Glioma Subspecialty Division. He specializes in precision minimally invasive targeted therapy for central nervous system tumors, particularly gliomas. His expertise extends to in-vivo genetic evolution studies of gliomas and the development of personalized treatment strategies.

Awards and Recognitions

Professor Bu is an esteemed expert enjoying special government allowances and has been recognized as an outstanding young science and technology expert, a young and middle-aged scientific and technological innovation talent, and a cross-century discipline leader. He has also been honored as an advanced individual returning from studying abroad and has received the Outstanding Youth and Outstanding Talent Innovation Fund. His contributions to the field have earned him a position as an expert evaluator for national science and technology awards and a candidate for the National “Hundred-Thousand-Ten Thousand Talents Project.”

Editorial and Professional Contributions

Professor Bu serves on the editorial boards of over ten prestigious medical journals, including the Journal of Clinical Neurosurgery and the Chinese Journal of Practical Diagnosis and Therapy. He is an active member of several key professional organizations, including the Glioma Committees of the Chinese Medical Doctor Association and the Chinese Anti-Cancer Association. Additionally, he holds leadership roles as the Deputy Chairman of the Neurosurgery Branch of the Henan Medical Association and the Neurosurgery and Cerebrovascular Disease Professional Committee of the Henan Medical Science Popularization Association.

Skills and Certifications

With extensive experience in neurosurgical precision techniques, Professor Bu has contributed to 15 published and ongoing patents. He has led 15 completed and two ongoing research projects, authored 22 SCI-indexed publications, and collaborated on multiple consultancy and industry projects. His work in minimally invasive surgery and personalized glioma treatment continues to push the boundaries of neurosurgical innovation, significantly impacting patient outcomes.

Research Focus

His research primarily explores gliomas, ctDNA, immunotherapy, precision medicine, gene evolution, minimally invasive surgery, and individualized treatment. His groundbreaking work on circulating tumor DNA (ctDNA) in tumor in-situ fluid (TISF) after glioma surgery has provided real-time, dynamic insights into the genetic evolution of gliomas. This research has significantly advanced the understanding of tumor recurrence, prognosis prediction, and immunotherapy strategies.

Conclusion

Given his remarkable achievements in glioma research, high-impact publications, leadership roles, and contributions to precision medicine, Dr. Xingyao Bu is highly suitable for the Best Researcher Award. His pioneering work has transformed the landscape of glioma treatment, making lasting contributions to the field of neurosurgery and oncology. Recognizing his excellence with this award would not only honor his past achievements but also inspire further advancements in brain tumor research.

Publications

Dynamics of tumor in situ fluid circulating tumor DNA in recurrent glioblastomas forecasts treatment efficacy of immune checkpoint blockade coupled with low-dose bevacizumab
Authors: D. Wang, J. Zhang, C. Bu, C. Ma, X. Bu
Journal: Journal of Cancer Research and Clinical Oncology, 2024
Predicting recurrent glioblastoma clinical outcome to immune checkpoint inhibition and low-dose bevacizumab with tumor in situ fluid circulating tumor DNA analysis
Authors: G. Guo, Z. Zhang, J. Zhang, T. Li, X. Bu
Journal: Cancer Immunology Immunotherapy, 2024
Molecular and clonal evolution in vivo reveal a common pathway of distant relapse gliomas
Authors: G. Liu, C. Bu, G. Guo, M. Li, X. Bu
Journal: iScience, 2023
Genomic alterations of oligodendrogliomas at distant recurrence
Authors: G. Liu, C. Bu, G. Guo, M. Li, X. Bu
Journal: Cancer Medicine, 2023
Fear stress promotes glioma progression through inhibition of ferroptosis by enhancing FSP1 stability
Authors: C. Bu, S. Hu, J. Yu, Z. Yan, X. Bu
Journal: Clinical and Translational Oncology, 2023

Prof. Dr. Xingyao Bu | Glioma | Best Researcher Award

Profile

Education